COMPANY PROFILE

Atalanta Therapeutics

Explore full profile

Pioneering RNAi treatments for neurodegenerative diseases

Boston, United StatesFounded 2018Biotech & Life Sciences

Valuation $250–500M Last recorded · 2025

Headcount <100 Current team size

Total funding $100–500M Disclosed equity funding

Unlock exact values

About Atalanta Therapeutics

Atalanta Therapeutics is a pioneering biotechnology company specializing in RNA interference (RNAi) to develop groundbreaking gene silencing therapies. The company focuses on creating branched small interfering RNA (siRNA) molecules that can halt diseases at their genetic source. Atalanta's primary clients include pharmaceutical companies and research institutions seeking advanced therapeutic solutions for genetic disorders. Operating in the biopharmaceutical market, Atalanta employs a business model centered on research and development, clinical trials, and strategic partnerships. Revenue is generated through licensing agreements, research collaborations, and milestone payments from successful clinical advancements. The company's innovative approach leverages Nobel Prize-winning science to offer a powerful therapeutic strategy for treating a wide range of diseases.

Source: Dealroom company data

At a glance

Status: Operational
Founded: 2018
Headquarters: Boston, United States
Employees: 39
Open positions: 1
Dealroom signal: 62.7/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Neurology, Genetics and genomics, Degenerative Diseases, RNA, Spinout, Biotech and Pharma, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn X

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Funding history

3 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES BOther financing	Jan 2025	$97M	$388M	RiverVest Venture Partners · Pictet · F-Prime · GHR Foundation	↗
SERIES AOther financing	Jan 2021	$110M	$440M	F-Prime	—

Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

Atalanta Therapeutics website traffic

Latest recorded traffic for Atalanta Therapeutics is 2.6K monthly website visits, down 23.5% over the last three months. Atalanta Therapeutics's team declined 32.8% over the past year.

Latest monthly visits2.6K 3-month web change-23.5% 1-year team growth-32.8%

Monthly website visitsJan 2021–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Open positions

Openings linked to this company in Dealroom

Senior/Principal Associate Scientist, NeuroscienceBoston, MA · Other · Aug 25, 2026 Senior/Principal Associate Scientist, In Vivo PharmacologyBoston, MA · Other · Aug 25, 2026 Senior Scientist, NeuroscienceBoston, MA · Other · Aug 25, 2026 Bioinformatics Analyst/EngineerBoston, Massachusetts, United States · Business Intelligence · Oct 19, 2025

4 distinct openings shownExplore hiring signals →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
LOLocanaCreating a new class of gene therapies by targeting disease-causing messenger RNA	San Diego, United States	Operational	7	$155M	$400M
MTMuna TherapeuticsDiscovering and developing transformative therapeutics for neurodegenerative diseases	Copenhagen, Denmark	Operational
HTHarness TherapeuticsA private biotechnology company, headquartered in Cambridge-UK, focused on the development of a novel class of therapeutic RNAs	Babraham, United Kingdom	Operational
CACARTANAGene expression mapping technology for brain tissue	Solna kommun, Sweden	Acquired
APAptaTargetsA clinical stage biopharmaceutical company focused in developing therapeutic applications based on aptamer technology	Madrid, Spain	Operational
MTmiCure TherapeuticsBiotech & Life Sciences	Ness Ziyyona, Israel	Operational
HDHorizon DiscoveryGene editing and modulation tools for research	Cambridge, United Kingdom	Acquired
ATAzureCell TherapiesRegenerative cell therapies for neurodegenerative disorders	Geneva, Switzerland	Operational